SLC16A1 and melanoma: Crizotinib inhibits CD147‐MCT1‐mediated lactate transport, suppressing melanoma growth and immune escape, prevents M2 macrophage polarization, and enhances immunotherapy by reducing CXCL13 via histone lactylation.